SCHEMBL1073473

SCHEMBL1073473

C1CCC(NC(=NC23CC4CC(CC(C4)C2)C3)N2CCOCC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
THPO P40225 1/20 0.53
PMP22 Q01453 1/20 0.53
MAPT P10636 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MCOLN3 Q8TDD5 1/20 0.51
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 1/20 0.45
EPHX2 P34913 4/20 0.44
USP2 O75604 1/20 0.39
EPHX1 P07099 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10619509 0.99 TSHR (0.55) TSHRCYP3A4CYP2D6THPOPMP22
SCHEMBL5280630 0.77 TSHR (0.61) TSHRCYP3A4CYP2D6THPOPMP22
SCHEMBL5280636 0.77 TSHR (0.61) TSHRCYP3A4CYP2D6THPOPMP22
Hydrochloric Acid SCHEMBL11706811 0.76 TSHR (0.64) TSHRCYP3A4CYP2D6THPOPMP22
Hydrochloric Acid SCHEMBL11706807 0.76 TSHR (0.64) TSHRCYP3A4CYP2D6THPOPMP22
SCHEMBL155224 0.74 CYP3A4 (0.57) TSHRCYP3A4CYP2D6THPOPMP22
SCHEMBL22402644 0.74 CYP3A4 (0.57) TSHRCYP3A4CYP2D6THPOPMP22
SCHEMBL139932 0.74 CYP3A4 (0.57) TSHRCYP3A4CYP2D6THPOPMP22
Hydrochloric Acid SCHEMBL11847105 0.73 CYP3A4 (0.59) TSHRCYP3A4CYP2D6THPOPMP22
Hydrochloric Acid SCHEMBL11843450 0.73 CYP3A4 (0.59) TSHRCYP3A4CYP2D6THPOPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0870757-B1 Fluoro-substituted adamantane derivatives PFIZER (US) 2002-06-12 EP claimed
US-6057364-A USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS PFIZER INC (US) 2000-05-02 US claimed
EP-0870757-A2 Fluoro-substituted adamantane derivatives PFIZER INC. (US) 1998-10-14 EP claimed
WO-1988008295-A1 HAIR GROWTH INHIBITION USING SUBSTITUED AMIDINES OR GUANIDINES THE UPJOHN COMPANY (US) 1988-11-03 WO claimed
US-4007181-A ANTIARRHYTHMIA, DIURETIC THE UPJOHN COMPANY (US) 1977-02-08 US claimed
US-20110201665-A1 Compositions, Methods, and Kits for Treating Influenza Viral Infections COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2011-08-18 US disclosed
US-20110028510-A1 Compositions, Methods, and Kits for Treating Influenza Viral Infections COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2011-02-03 US disclosed
WO-2011001258-A1 COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES EVITA LIFE SCIENCE PTE. LTD (SG) 2011-01-06 WO disclosed
WO-2010095041-A2 COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS EXCRX (SINGAPORE) PTE.LTD. (SG) 2010-08-26 WO disclosed
US-20060270742-A1 Compositions and methods for the treatment of neurodegenerative diseases COMBINATORX, INC. 2006-11-30 US disclosed
WO-2006119295-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES COMBINATORX, INCORPORATED (US) 2006-11-09 WO disclosed
EP-0870757-B1 Fluoro-substituted adamantane derivatives PFIZER (US) 2002-06-12 EP disclosed
US-6057364-A USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS PFIZER INC (US) 2000-05-02 US disclosed
EP-0870757-A2 Fluoro-substituted adamantane derivatives PFIZER INC. (US) 1998-10-14 EP disclosed
WO-1988008295-A1 HAIR GROWTH INHIBITION USING SUBSTITUED AMIDINES OR GUANIDINES THE UPJOHN COMPANY (US) 1988-11-03 WO disclosed
US-4007181-A ANTIARRHYTHMIA, DIURETIC THE UPJOHN COMPANY (US) 1977-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270742-A1 Compositions and methods for the treatment of neurodegenerative diseases PSEN2, PSEN1, HTT TSHR 4729/4885CYP3A4 4742/4885CYP2D6 4670/4885
US-20110201665-A1 Compositions, Methods, and Kits for Treating Influenza Viral Infections IL5, CCL5, CCL11 TSHR 4258/4885CYP3A4 2335/4885CYP2D6 3350/4885
US-20110028510-A1 Compositions, Methods, and Kits for Treating Influenza Viral Infections IL5, CCL5, CCL11 TSHR 4258/4885CYP3A4 2335/4885CYP2D6 3350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.